Crime Cases Still Using Cassettes
Technology0 min ago
Couple Forced To Sell Home After Nhs Refuse To Fund Daughter's Treatment For Rare Illness.
63 Answers
http://
Perhaps if she was a non UK citizen and suffering from a self inflicted illness, there would be no problem?
Perhaps if she was a non UK citizen and suffering from a self inflicted illness, there would be no problem?
Answers
Best Answer
No best answer has yet been selected by anotheoldgit. Once a best answer has been selected, it will be shown here.
For more on marking an answer as the "Best Answer", please visit our FAQ.
@hc4361
//Some drugs do use very, very expensive ingredients. //
I would have thought the most expensive part would be the safety trials, animal then human, followed by the double-blind efficacy testing.
That last bit would be tricky if it is the kind of condition where the occurrence rate is so low that we have to pool patients with other countries to get a group big enough to obtain meaningful efficacy results. International cooperation doesn't come cheap.
Drugs for rare medical conditions will always suffer similar economics to that of luxury cars:- similar design, tooling and launch cost as less exotic designs but fewer units will be sold so the unit cost has to be higher… and, possibly, not come down as time passes because the development cost would have been in the millions (both for cars and medicines).
Brutal as it sounds, the question is whether the NHS remit extends as far as bespoke"one-off" treatments or whether it should stick to common complaints, treatable at a cost commensurate with average worker's contributions?
(Or am I drifting into bean-counter territory myself, now?)
//Some drugs do use very, very expensive ingredients. //
I would have thought the most expensive part would be the safety trials, animal then human, followed by the double-blind efficacy testing.
That last bit would be tricky if it is the kind of condition where the occurrence rate is so low that we have to pool patients with other countries to get a group big enough to obtain meaningful efficacy results. International cooperation doesn't come cheap.
Drugs for rare medical conditions will always suffer similar economics to that of luxury cars:- similar design, tooling and launch cost as less exotic designs but fewer units will be sold so the unit cost has to be higher… and, possibly, not come down as time passes because the development cost would have been in the millions (both for cars and medicines).
Brutal as it sounds, the question is whether the NHS remit extends as far as bespoke"one-off" treatments or whether it should stick to common complaints, treatable at a cost commensurate with average worker's contributions?
(Or am I drifting into bean-counter territory myself, now?)
ummmm
/// I think it's aimed at the OP. ///
Get your facts right
Fusion5 16:35 Mon
*** Poor kid. Perhaps if we stopped giving free treatment to overseas freeloaders who have paid nothing into the NHS, the purse may be a little fuller. Sadly this Will never happen. ***
mikey4444 16:37 Mon
*** Another attempt at playing the race/immigration card ! ***
/// I think it's aimed at the OP. ///
Get your facts right
Fusion5 16:35 Mon
*** Poor kid. Perhaps if we stopped giving free treatment to overseas freeloaders who have paid nothing into the NHS, the purse may be a little fuller. Sadly this Will never happen. ***
mikey4444 16:37 Mon
*** Another attempt at playing the race/immigration card ! ***
Latest Posts
Crosswords1 min ago
ChatterBank4 mins ago
ChatterBank4 mins ago
Quizzes & Puzzles5 mins ago
Related Questions
Sorry, we can't find any related questions. Try using the search bar at the top of the page to search for some keywords, or choose a topic and submit your own question.